The HRs for OS for patients with PD-L1–positive disease versus PD-L1–negative disease presented above (where OS was defined as the time from initial SCLC diagnosis to death) were similar to those in the total population when OS was defined as the time from diagnosis of ES-SCLC to death in all patients with ES-SCLC, or among the 70 patients with ES-SCLC tumor specimens (data not shown). The gene discussed is CD274; the disease is neoplasm.